Product Code:	LTR-CV2-NCR-4
Protein:	SARS-CoV-2 Nucleocapsid, RNA binding domain (aa 46- aa 173)
Volume:	1mg
Source:	E. coli
Mol. Wt:	15 kD
Purification:	Purified from E. coli by multi-step chromatography.
Purity:	Purity >95% by silver stain SDS-PAGE and InBio®MS (LC-MS/MS, relative abundance).
Validation:	Validated by IgG antibody ELISA using serum samples (n=10) from COVID-19 patients.
Concentration:	xx based on OD 280nm. Extinction Coefficient = 1.8.
Formulation:	Preservative and carrier-free in 0.3M NaCl, 1X PBS, pH 7.4. Filtered through 0.22µm filter.
Storage:	Store at -20ºC. Avoid repeated freeze-thaw cycles.
Notes:	(1) SARS-CoV-2 NCR has a C-terminal 7xHis-tag. (2) Point mutation (P46G) introduced to increase stability. (3) A LoTox™ product, Endotoxin < 0.03 EU/µg.
For research and commercial use in vitro: not for human in vivo or therapeutic use. An InBio® product. Made in the USA

indoor biotechnologies很高兴将其重组蛋白的开发工作扩展到包括与过敏和哮喘有关的病毒蛋白。人鼻病毒16（HRV-16）表面蛋白VP1，VP2和VP0（VP2和VP4的融合体）被高质量生产。HRV衣壳蛋白提供了有用的工具，可用于研究鼻病毒诱发的哮喘加重所涉及的免疫机制，以及用于表位作图，T细胞反应和诊断目的。由于广泛的蛋白质-蛋白质相互作用，鼻病毒蛋白质难以单独表达。通过使用专有的纯化和制造方案，Indoor Biotechnologies开发了许多HRV-16 VP1，VP2和VP0，这些均已通过Western blotting验证。